{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050406","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.356606+00:00","generated_at":"2026-05-16T23:01:14.735608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanuwave Q3 record revenue $11.5M (+22% YoY); guides Q4 $13-14M","bullets":["Revenue of $11.5M, up 22% YoY and 13% sequentially; highest quarterly revenue in company history.","GAAP operating income $1.5M vs $2.0M YoY, impacted by $1.4M stock-based compensation (none in Q3 2024).","Net income $10.3M vs net loss of $20.7M YoY, driven by $6.1M non-cash derivative gain and $5.0M patent sale.","Adjusted EBITDA grew to $3.5M from $2.1M YoY.","Q4 2025 revenue guidance $13-14M; full-year FY2025 revenue guidance $44-45M (35-39% growth over FY2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050406","json":"https://secwatch.observer/filing/0001628280-25-050406.json","markdown":"https://secwatch.observer/filing/0001628280-25-050406.md","text":"https://secwatch.observer/filing/0001628280-25-050406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025050406/0001628280-25-050406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025050406/snwv-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:01:14.735608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}